Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles

Immunology and Cell Biology

Volumn 84, Issue 3, 2006, Pages 318-330

  Viatte, Sebastien ^b   Alves, Pedro M ^b   Romero, Pedro ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b NONE

Author keywords

Cytolytic T lymphocyte (CTL); Immunotherapy; Tumour antigen

Indexed keywords

CD8 ANTIGEN; GENE PRODUCT; HLA ANTIGEN; PROTEASOME; TUMOR ANTIGEN;

ALGORITHM; ANALYTIC METHOD; ANTIGEN DETECTION; CD8+ T LYMPHOCYTE; COST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; MOLECULAR RECOGNITION; NONHUMAN; REVERSE IMMUNOLOGY; REVIEW; T LYMPHOCYTE; TUMOR IMMUNOLOGY; VACCINATION; VALIDATION PROCESS;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33646119668     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2006.01447.x     Document Type: Review

References (165)

1. Cerottini JC Nordin AA Brunner KT. In vitro cytotoxic activity of thymus cells sensitized to alloantigens. Nature 1970 227 72 3.
2. Cerottini JC Nordin AA Brunner KT. Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature 1970 228 1308 309.
3. Zinkernagel RM Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974 248 701 702.
4. Zinkernagel RM. Restriction by H-2 gene complex of transfer of cell-mediated immunity to Listeria monocytogenes. Nature 1974 251 230 33.
5. Bjorkman PJ Saper MA Samraoui B Bennett WS Strominger JL Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987 329 506 12.
6. Bjorkman PJ Saper MA Samraoui B Bennett WS Strominger JL Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987 329 512 18.
7. Gascoigne NR Chien Y Becker DM Kavaler J Davis MM. Genomic organization and sequence of T-cell receptor beta-chain constant- and joining-region genes. Nature 1984 310 387 91.
8. Patten P Yokota T Rothbard J Chien Y Arai K Davis MM. Structure, expression and divergence of T-cell receptor beta-chain variable regions. Nature 1984 312 40 46.
9. Yanagi Y Yoshikai Y Leggett K Clark SP Aleksander I Mak TW. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 1984 308 145 9.
10. Yoshikai Y Anatoniou D Clark SP et al. Sequence and expression of transcripts of the human T-cell receptor beta-chain genes. Nature 1984 312 521 4.
11. Falk K Rotzschke O Stevanovic S Jung G Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991 351 290 96.
12. Ruppert J Sidney J Celis E Kubo RT Grey HM Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993 74 929 37.
13. Wilson DB Wilson DH Schroder K et al. Specificity and degeneracy of T cells. Mol. Immunol. 2004 40 1047 55.
14. Knuth A Danowski B Oettgen HF Old LJ. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl Acad. Sci. USA 1984 81 3511 15.
15. van der Bruggen P Traversari C Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 1643 7.
16. Brouwenstijn N Gaugler B Kruse KM et al. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int. J. Cancer 1996 68 177 82.
17. Echchakir H Mami-Chouaib F Vergnon I et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 2001 61 4078 83.
18. Wang RF Johnston SL Zeng G Topalian SL Schwartzentruber DJ Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 1998 161 3598 606.
19. Steinman RM Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004 305 197 200.
20. Jager E Jager D Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 2003 106 817 20.
21. Blattman JN Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004 305 200 205.
22. Romero P Pittet M Dutoit V et al. Therapeutic cancer vaccines based on molecularly defined human tumor antigens. Vaccine 2002 20 Suppl. 4 A2 A7.
23. Speiser DE Pittet MJ Rimoldi D et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 2003 13 461 72.
24. Belardelli F Ferrantini M Parmiani G Schlom J Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. 2004 64 6827 30.
25. Reynolds SR Zeleniuch-Jacquotte A Shapiro RL et al. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 2003 9 657 62.
26. Celis E Tsai V Crimi C et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl Acad. Sci. USA 1994 91 2105 9.
27. Boon T van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996 183 725 9.
28. Maecker B von Bergwelt-Baildon Anderson KS Vonderheide RH Schultze JL. Linking genomics to immunotherapy by reverse immunology -'immunomics' in the new millennium. Curr. Mol. Med. 2001 1 609 19.
29. Tanzarella S Fleischhauer K van Endert P Bordignon C Traversari C. Characterization of antigenic peptide epitopes by reverse immunology: induction of cytotoxic T lymphocytes specific for exogenous peptide only. Int. J. Cancer 1997 72 912 15.
30. Paschen A Eichmuller S Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol. Immunother. 2004 53 196 203.
31. Van Der Bruggen P Zhang Y Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 2002 188 51 64.
32. Satoh M Takamiya Y Oka S Tokunaga K Takiguchi M. Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601. Vaccine 2005 23 3783 90.
33. Britten CM Meyer RG Graf C Huber C Wolfel T. Identification of T cell epitopes by the use of rapidly generated mRNA fragments. J. Immunol. Methods 2005 299 165 75.
34. Capo S Nuti S Scarselli M et al. Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells. Vaccine 2005 23 5028 37.
35. Hammond AS Klein MR Corrah T et al. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes. Clin. Exp. Immunol. 2005 140 109 16.
36. Fonseca SG Moins-Teisserenc H Clave E et al. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect. 2005 7 688 97.
37. Hassainya Y Garcia-Pons F Kratzer R et al. Identification of naturally processed HLA-A2 - restricted proinsulin epitopes by reverse immunology. Diabetes 2005 54 2053 9.
38. Fujie T Tahara K Tanaka F Mori M Takesako K Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int. J. Cancer 1999 80 169 72.
39. Kawashima I Hudson SJ Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 1998 59 1 14.
40. van der Bruggen P Bastin J Gajewski T et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 1994 24 3038 43.
41. Herman J van der Bruggen P Luescher IF et al. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996 43 377 83.
42. Tanaka F Fujie T Tahara K et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. 1997 57 4465 8.
43. Parkhurst MR Fitzgerald EB Southwood S Sette A Rosenberg SA Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998 58 4895 901.
44. Tsai V Southwood S Sidney J et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997 158 1796 802.
45. Ayyoub M Stevanovic S Sahin U et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 2002 168 1717 22.
46. Kessler JH Beekman NJ Bres-Vloemans SA et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 2001 193 73 88.
47. Alves PM Faure O Graff-Dubois S et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res. 2003 63 8476 80.
48. van den Eynde B van der Bruggen P. T cell defined tumor antigens. Cited 2006. Available from URL http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm.
49. Princiotta MF Finzi D Qian SB et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003 18 343 54.
50. Schubert U Anton LC Gibbs J Norbury CC Yewdell JW Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000 404 770 74.
51. Faure O Graff-Dubois S Bretaudeau L et al. Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Int. J. Cancer 2004 108 863 70.
52. Chen YT Scanlan MJ Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 1997 94 1914 18.
53. Tureci O Sahin U Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today 1997 3 342 9.
54. Jager D Taverna C Zippelius A Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother. 2004 53 144 7.
55. Wadle A Mischo A Imig J et al. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int. J. Cancer 2005 117 104 13.
56. Fernandez Madrid F Tang N Alansari H Karvonen RL Tomkiel JE. Improved approach to identify cancer-associated autoantigens. Autoimmun. Rev. 2005 4 230 35.
57. Cui JW Li WH Wang J et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol. Cell Proteomics 2005 4 1718 24.
58. Prasannan L Misek DE Hinderer R Michon J Geiger JD Hanash SM. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin. Cancer Res. 2000 6 3949 56.
59. Ye B Cramer DW Skates SJ et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003 9 2904 11.
60. Lapointe J Li C Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 2004 101 811 16.
61. Higgins JP Shinghal R Gill H et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am. J. Pathol. 2003 162 925 32.
62. Sugita M Geraci M Gao B et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002 62 3971 9.
63. Imbeaud S Auffray C. 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. Drug Discov. Today 2005 10 1175 82.
64. Velculescu VE Zhang L Vogelstein B Kinzler KW. Serial analysis of gene expression. Science 1995 270 484 7.
65. Brenner S Johnson M Bridgham J et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 2000 18 630 34.
66. Martelange V De Smet C De Plaen E Lurquin C Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. 2000 60 3848 55.
67. Kawakami Y Fujita T Matsuzaki Y et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci. 2004 95 784 91.
68. Van den Eynde BJ van der Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol. 1997 9 684 93.
69. Pollock JD. Gene expression profiling: methodological challenges, results, and prospects for addiction research. Chem. Phys. Lipids 2002 121 241 56.
70. Stolovitzky GA Kundaje A Held GA et al. Statistical analysis of MPSS measurements: application to the study of LPS-activated macrophage gene expression. Proc. Natl Acad. Sci. USA 2005 102 1402 7.
71. de Wit NJ Cornelissen IM Diepstra JH Weidle UH Ruiter DJ van Muijen GN. The MMA1 gene family of cancer-testis antigens has multiple alternative splice variants: characterization of their expression profile, the genomic organization, and transcript properties. Genes Chromosomes Cancer 2005 42 10 21.
72. de Wit NJ Weidle UH Ruiter DJ van Muijen GN. Expression profiling of MMA-1a and splice variant MMA-1b: new cancer/testis antigens identified in human melanoma. Int. J. Cancer 2002 98 547 53.
73. Wenzel K Felix SB Flachmeier C et al. Identification and characterization of KAT, a novel gene preferentially expressed in several human cancer cell lines. Biol. Chem. 2003 384 763 75.
74. Yousef GM White NM Michael IP et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol. 2005 26 227 35.
75. Hui L Zhang X Wu X et al. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 2004 23 3013 23.
76. Wang Z Lo HS Yang H et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 2003 63 655 7.
77. Sperisen P Iseli C Pagni M Stevenson BJ Bucher P Jongeneel CV. trome, trEST and trGEN: databases of predicted protein sequences. Nucleic Acids Res. 2004 32 D509 11.
78. Brusic V Bajic VB Petrovsky N. Computational methods for prediction of T-cell epitopes - a framework for modelling, testing, and applications. Methods 2004 34 436 43.
79. Udaka K Wiesmuller KH Kienle S et al. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. Immunogenetics 2000 51 816 28.
80. BioInformatics and Molecular Analysis Section, Center for Information Technology. HLA Peptide Binding Predictions. Cited March 2005. Available from URL http://bimas.dcrt.nih.gov/molbio/hla_bind/.
81. Parker KC Bednarek MA Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994 152 163 75.
82. Department of Immunology, Institute for Cell Biology BMI-Heidelberg. Cited July 2005. Available from URL http://www.syfpeithi.de/.
83. Rammensee H Bachmann J Emmerich NP Bachor OA Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999 50 213 19.
84. Stevanovic S. Antigen processing is predictable: from genes to T cell epitopes. Transpl. Immunol. 2005 14 171 4.
85. Sidney J Southwood S Sette A. Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires. Immunogenetics 2005 57 393 408.
86. Tan TL Geluk A Toebes M Ottenhoff TH Drijfhout JW. A novel, highly efficient peptide-HLA class I binding assay using unfolded heavy chain molecules: identification of HIV-1 derived peptides that bind to HLA-A*0201 and HLA-A*0301. J. Immunol. Methods 1997 205 201 9.
87. Kast WM Brandt RM Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 1994 152 3904 12.
88. Ljunggren HG Stam NJ Ohlen C et al. Empty MHC class I molecules come out in the cold. Nature 1990 346 476 80.
89. Kelly A Powis SH Kerr LA et al. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 1992 355 641 4.
90. Pogue RR Eron J Frelinger JA Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl Acad. Sci. USA 1995 92 8166 70.
91. Kessler JH Mommaas B Mutis T et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 2003 64 245 55.
92. Maryanski JL Pala P Cerottini JC Corradin G. Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA. J. Exp. Med. 1988 167 1391 405.
93. Townsend A Elliott T Cerundolo V Foster L Barber B Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell 1990 62 285 95.
94. Elvin J Potter C Elliott T Cerundolo V Townsend A. A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J. Immunol. Methods 1993 158 161 71.
95. Fahnestock ML Tamir I Narhi L Bjorkman PJ. Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule. Science 1992 258 1658 62.
96. Ottenhoff TH Geluk A Toebes M Benckhuijsen WE van Meijgaarden KE Drijfhout JW. A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. J. Immunol. Methods 1997 200 89 97.
97. Olsen AC Pedersen LO Hansen AS et al. A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. Eur. J. Immunol. 1994 24 385 92.
98. Dedier S Reinelt S Rion S Folkers G Rognan D. Use of fluorescence polarization to monitor MHC-peptide interactions in solution. J. Immunol. Methods 2001 255 57 66.
99. Buchli R VanGundy RS Hickman-Miller HD Giberson CF Bardet W Hildebrand WH. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201 - a new tool for epitope discovery. Biochemistry 2005 44 12 491 507.
100. Pascolo S. HLA class I transgenic mice: development, utilisation and improvement. Expert Opin. Biol. Ther. 2005 5 919 38.
101. Arnold B Hammerling GJ. MHC class-I transgenic mice. Annu. Rev. Immunol. 1991 9 297 322.
102. Borbulevych OY Baxter TK Yu Z Restifo NP Baker BM. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 2005 174 4812 20.
103. Hernandez J Schoeder K Blondelle SE et al. Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur. J. Immunol. 2004 34 2331 41.
104. Baratin M Kayibanda M Ziol M et al. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope. J. Pept. Sci. 2002 8 327 34.
105. Hall FC Rabinowitz JD Busch R et al. Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur. J. Immunol. 2002 32 662 70.
106. van der Burg SH Visseren MJ Brandt RM Kast WM Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 1996 156 3308 14.
107. De Visser KE Schumacher TN Kruisbeek AM. CD8+ T cell tolerance and cancer immunotherapy. J. Immunother. 2003 26 1 11.
108. Graff-Dubois S Faure O Gross DA et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 2002 169 575 80.
109. Machlenkin A Paz A Bar Haim E et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res. 2005 65 6435 42.
110. Montes M Rufer N Appay V et al. Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin. Exp. Immunol. 2005 142 292 302.
111. Salio M Shepherd D Dunbar PR et al. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J. Immunol. 2001 167 1188 97.
112. Dupont J Latouche JB Ma C Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005 65 5417 27.
113. Oelke M Maus MV Didiano D June CH Mackensen A Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 2003 9 619 24.
114. Rodeberg DA Nuss RA Elsawa SF Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin. Cancer Res. 2005 11 4545 52.
115. Schultze JL Michalak S Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 1997 100 2757 65.
116. Alexander J Sidney J Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994 1 751 61.
117. Kratz PA Bottcher B Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA 1999 96 1915 20.
118. Etlinger HM Gillessen D Lahm HW Matile H Schonfeld HJ Trzeciak A. Use of prior vaccinations for the development of new vaccines. Science 1990 249 423 5.
119. Sutmuller RP van Duivenvoorde LM van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001 194 823 32.
120. Chen WF Wilson A Scollay R Shortman K. Limit-dilution assay and clonal expansion of all T cells capable of proliferation. J. Immunol. Methods 1982 52 307 22.
121. Oelke M Kurokawa T Hentrich I et al. Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand. J. Immunol. 2000 52 544 9.
122. Valmori D Pittet MJ Rimoldi D et al. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 1999 59 2167 73.
123. Migliaccio M Raj K Menzel O Rufer N. Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes. J. Immunol. 2005 174 3335 43.
124. Rufer N Migliaccio M Antonchuk J Humphries RK Roosnek E Lansdorp PM. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001 98 597 603.
125. Barsov EV Andersen H Coalter VJ Carrington M Lifson JD Ott DE. Capture of antigen-specific T lymphocytes from human blood by selective immortalization to establish long-term T-cell lines maintaining primary cell characteristics. Immunol. Lett. 2005.
126. Verra NC Jorritsma A Weijer K et al. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. 2004 64 2153 61.
127. Hooijberg E Ruizendaal JJ Snijders PJ Kueter EW Walboomers JM Spits H. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J. Immunol. 2000 165 4239 45.
128. Aarnoudse CA Kruse M Konopitzky R Brouwenstijn N Schrier PI. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. Int. J. Cancer 2002 99 7 13.
129. Calogero A Hospers GA Kruse KM et al. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res. 2000 20 1793 9.
130. Rufer N Reichenbach P Romero P. Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol. Med. 2005 109 265 84.
131. Lethe B van der Bruggen P Brasseur F Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 1997 7 Suppl. 2 S83 8.
132. Dutoit V Rubio-Godoy V Dietrich PY et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 2001 61 5850 56.
133. Gati A Guerra N Giron-Michel J et al. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res. 2001 61 3240 44.
134. Gati A Guerra N Gaudin C et al. CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling. Cancer Res. 2003 63 7475 82.
135. Blank C Brown I Peterson AC et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 64 1140 45.
136. Gajewski TF Fallarino F Fields PE Rivas F Alegre ML. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J. Immunol. 2001 166 3900 907.
137. Coles MC McMahon CW Takizawa H Raulet DH. Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors. Eur. J. Immunol. 2000 30 236 44.
138. Ugolini S Vivier E. Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr. Opin. Immunol. 2000 12 295 300.
139. Nishimura H Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001 22 265 8.
140. Ikeda H Lethe B Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997 6 199 208.
141. Ayyoub M Migliaccio M Guillaume P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur. J. Immunol. 2001 31 2642 51.
142. Romero P Valmori D Pittet MJ et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 2002 188 81 96.
143. Echchakir H Dorothee G Vergnon I Menez J Chouaib S Mami-Chouaib F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl Acad. Sci. USA 2002 99 9358 63.
144. Nagorsen D Scheibenbogen C Marincola FM Letsch A Keilholz U. Natural T cell immunity against cancer. Clin. Cancer Res. 2003 9 4296 303.
145. Valmori D Gileadi U Servis C et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 1999 189 895 906.
146. Reits E Griekspoor A Neijssen J et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 2003 18 97 108.
147. Uebel S Tampe R. Specificity of the proteasome and the TAP transporter. Curr. Opin. Immunol. 1999 11 203 8.
148. Reits E Neijssen J Herberts C et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004 20 495 506.
149. Toes RE Nussbaum AK Degermann S et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 2001 194 1 12.
150. van Hall T Sijts A Camps M et al. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 2000 192 483 94.
151. Schultz ES Chapiro J Lurquin C et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 2002 195 391 9.
152. Morel S Levy F Burlet-Schiltz O et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000 12 107 17.
153. Kuckelkorn U Ruppert T Strehl B et al. Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J. Exp. Med. 2002 195 983 90.
154. Meidenbauer N Zippelius A Pittet MJ et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res. 2004 64 6319 26.
155. Hanada K Yewdell JW Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004 427 252 6.
156. Vigneron N Stroobant V Chapiro J et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004 304 587 90.
157. Godefroy E Moreau-Aubry A Diez E Dreno B Jotereau F Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J. Exp. Med. 2005 202 61 72.
158. Nielsen M Lundegaard C Lund O Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005 57 33 41.
159. Larsen MV Lundegaard C Lamberth K et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur. J. Immunol. 2005 35 2295 303.
160. Uebel S Kraas W Kienle S Wiesmuller KH Jung G Tampe R. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Proc. Natl Acad. Sci. USA 1997 94 8976 81.
161. Liao X Li Y Bonini C et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol. Ther. 2004 9 757 64.
162. Bonehill A Heirman C Tuyaerts S et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 2004 172 6649 57.
163. Tsomides TJ Reilly EB Eisen HN. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response. Int. Immunol. 1997 9 327 38.
164. Schirle M Keilholz W Weber B et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 2000 30 2216 25.
165. Singh-Jasuja H Emmerich NP Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 2004 53 187 195.